Author

Lukas Minder

University of ZurichORCID 0009-0002-0200-7938Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cell Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:cell signaling & trafficking· 1 Assay:proteomics· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Andrea LaimbacheriD· 3 shared Gabriela KaniaiD· 3 shared Oliver DistleriD· 3 shared Przemysław BłyszczukiD· 3 shared Alicja BraczkoiD· 2 shared Barbara Anna Kutryb-ZająciD· 2 shared Dawid WnukiD· 2 shared Jarosław CzyżiD· 2 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCell Biology

Andrea LaimbacherORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Dysferlin is a novel regulator of COMP-positive matrifibrocytes in heart failure

Ievgeniia Kocherova, Muriel Giger, Andrea Laimbacher, Lukas Minder, Daria Nurzyńska, Franca Di Meglio, Gino Andrea Bonazza, Elena Pachera, Filip Rolski, Michał Ma̧czewski, Przemysław Leszek, Michele Visentin, Oliver Distler, Przemysław Błyszczuk, Gabriela Kania

This study identifies dysferlin as an antifibrotic regulator that limits fibroblast differentiation and myocardial fibrosis in heart failure.

bioRxiv · Aug 21, 2026 · PreprintCell Biology

Lanifibranor (IVA-337) - a pan-PPAR agonist suppresses TGF-β1-induced cardiac fibrosis and rescues cardiomyocyte function

Milena Paw, Lukas Minder, Andrea Laimbacher, Patrycja Kaczara, Magdalena Czepiec, Sylwia Bobis‐Wozowicz, Dawid Wnuk, Barbara Anna Kutryb-Zając, Alicja Braczko, Michał Sarna, Stefan Chłopicki, Zbigniew Madeja, Oliver Distler, Przemysław Błyszczuk, Jarosław Czyż, Gabriela Kania

This study shows lanifibranor reduces TGF-β1-induced cardiac fibrosis and improves cardiomyocyte function in human models.

bioRxiv · Aug 21, 2026 · PreprintPharmacology & Toxicology

The dual PPAR-α/δ agonist elafibranor attenuates TGF-β1-induced cardiac fibrosis through redox-metabolic and bioenergetic reprogramming in human cardiac models

Milena Paw, Lukas Minder, Andrea Laimbacher, Magdalena Czepiec, Sylwia Bobis‐Wozowicz, Dawid Wnuk, Barbara Anna Kutryb-Zając, Alicja Braczko, Michał Sarna, Patrycja Kaczara, Stefan Chłopicki, Zbigniew Madeja, Oliver Distler, Przemysław Błyszczuk, Jarosław Czyż, Gabriela Kania

This paper shows that elafibranor reduces TGF-β1-induced cardiac fibrosis by improving redox-metabolic and bioenergetic processes in human cardiac models.

bioRxiv · Aug 21, 2026 · PreprintCell Biology